TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Polycystic Ovary Syndrome (PCOS) - The Female Metabolic Syndrome Genes And Processes In The Aetiology And Pathogenesis Of PCOS And Identification Of New Treatment Strategies
Brief Summary: Hypothesis:

The overall hypothesis is that women with PCOS, both obese and non-obese, have larger adipocytes, altered metabolism and signs of inflammation in adipose tissue and that these changes are associated with high sympathetic nerve activity, hyperandrogenism hyperinsulinaemia, insulin resistance with progression to type II diabetes and cardiovascular disease (CVD) as well as psychological distress and reduced quality of life. Physical exercise and electro-acupuncture decrease high concentrations of androgens, induce regulare menstrual pattern, inhibits high sympathetic activity and restore the PCOS induced disturbances.


Options:
A: Arm Label: Low-frequency electro-acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: Physical exercise; Type: EXPERIMENTAL; Interventions: Procedure: Physical exercise | Arm Label: Untreated control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Untreated control | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): Low-frequency electro-acupuncture | Intervention Type: PROCEDURE; Name: Physical exercise; Assigned to Arm(s): Physical exercise | Intervention Type: PROCEDURE; Name: Untreated control; Assigned to Arm(s): Untreated control
B: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: strength training; Type: EXPERIMENTAL; Interventions: Behavioral: strength training | Arm Label: interval training; Type: EXPERIMENTAL; Interventions: Behavioral: interval training | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: strength training; Assigned to Arm(s): strength training | Intervention Type: BEHAVIORAL; Name: interval training; Assigned to Arm(s): interval training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MEASURES OF GAIT AND SELF-REPORTED PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: A RANDOMIZED, SINGLE-BLIND WASHOUT, DOUBLE-BLIND TREATMENT, DOUBLE DUMMY CROSS-OVER PILOT TRIAL USING PLACEBO, OXYCODONE AND CELECOXIB (A9011030)
Brief Summary: The Purpose of this trial is to evaluate the use of a cross-over trial design in an osteoarthritis population. We will determine the inter- and intra-subject variability in osteoarthritis (OA) endpoints and evaluate if efficacy can be detected by measuring OA endpoints following treatment with 2 different types of analgesics in a crossover study of this design.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone IR | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (CG5503) | Arm Label: 006; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone CR | Arm Label: 007; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone CR; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: oxycodone IR; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Tapentadol ER (CG5503); Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 007
C: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
D: Intervention Type: DRUG; Name: glucosamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chondroitin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glucosamine and chondroitin sulfate combined; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigating the Effect of Intra-operative Infiltration With Local Anaesthesia on the Development of Chronic Postoperative Pain After Inguinal Hernia Repair. A Randomized Placebo Controlled Triple Blinded and Group Sequential Study Design
Brief Summary: The effect of intraoperative infiltration of the operation site with bupivacain on the development of chronic pain is the object of our trial. We hypothesize that the occurrence of chronic pain in the goup of patients receiving the infiltration will be 50% less than in the placebo group receiving normal saline. The study is a randomized controlled triple blinded trial with a sequential study design.


Options:
A: Arm Label: 0.25% Ropivicaine; Type: EXPERIMENTAL; Interventions: Drug: Ropivicaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ropivicaine; Assigned to Arm(s): 0.25% Ropivicaine
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
C: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
D: Arm Label: Patients who had inguinal herniorraphy.; Type: N/A; Interventions: Procedure: Inguinal herniorraphy. | Arm Label: Patients who had hysterectomy.; Type: N/A; Interventions: Procedure: Hysterectomy. | Arm Label: Patients who had thoracotomy.; Type: N/A; Interventions: Procedure: Thoracotomy . | Intervention Type: PROCEDURE; Name: Inguinal herniorraphy.; Assigned to Arm(s): Patients who had inguinal herniorraphy. | Intervention Type: PROCEDURE; Name: Hysterectomy.; Assigned to Arm(s): Patients who had hysterectomy. | Intervention Type: PROCEDURE; Name: Thoracotomy .; Assigned to Arm(s): Patients who had thoracotomy.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigating the Effect of Intra-operative Infiltration With Local Anaesthesia on the Development of Chronic Postoperative Pain After Inguinal Hernia Repair. A Randomized Placebo Controlled Triple Blinded and Group Sequential Study Design
Brief Summary: The effect of intraoperative infiltration of the operation site with bupivacain on the development of chronic pain is the object of our trial. We hypothesize that the occurrence of chronic pain in the goup of patients receiving the infiltration will be 50% less than in the placebo group receiving normal saline. The study is a randomized controlled triple blinded trial with a sequential study design.


Options:
A: Arm Label: ropivacaine + methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: ropivacaine 0.2%, Drug: Methylprednisolone 1mg/kg | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline 0.9% | Intervention Type: DRUG; Name: ropivacaine 0.2%; Assigned to Arm(s): ropivacaine + methylprednisolone | Intervention Type: DRUG; Name: Methylprednisolone 1mg/kg; Assigned to Arm(s): ropivacaine + methylprednisolone | Intervention Type: DRUG; Name: saline 0.9%; Assigned to Arm(s): saline
B: Arm Label: Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Bupivacaine | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Saline
C: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
D: Arm Label: 0.25% Ropivicaine; Type: EXPERIMENTAL; Interventions: Drug: Ropivicaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ropivicaine; Assigned to Arm(s): 0.25% Ropivicaine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigating the Effect of Intra-operative Infiltration With Local Anaesthesia on the Development of Chronic Postoperative Pain After Inguinal Hernia Repair. A Randomized Placebo Controlled Triple Blinded and Group Sequential Study Design
Brief Summary: The effect of intraoperative infiltration of the operation site with bupivacain on the development of chronic pain is the object of our trial. We hypothesize that the occurrence of chronic pain in the goup of patients receiving the infiltration will be 50% less than in the placebo group receiving normal saline. The study is a randomized controlled triple blinded trial with a sequential study design.


Options:
A: Arm Label: Gabapentin preoperatively; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Active placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diphenhydramine | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin preoperatively | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Active placebo
B: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ropivacaine, ketorelac and epinephrine | Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: ropivacaine, ketorelac and epinephrine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): P

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events
Brief Summary: The purpose of REAL-LATE (Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events) trial is to assess the relationship between clopidogrel use and long-term rates of cardiac death or MI after DES implantation in real-world practice and to estimate the duration of dual antiplatelet therapy for preventing the late thrombotic events.


Options:
A: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Arm Label: aspirin low responders monotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: aspirin low responders dual antiplatelet therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): aspirin low responders dual antiplatelet therapy
D: Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair.
Brief Summary: The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.


Options:
A: Arm Label: Bupivacaine and low dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine and high dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: High dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Intervention Type: DRUG; Name: Questionnaire and Physical Exam; Assigned to Arm(s): Bupivacaine, Bupivacaine and high dose SKY0402, Bupivacaine and low dose SKY0402, High dose SKY0402
B: Arm Label: Bupivacaine HCl 105mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402 low dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 Middle dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 High dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl 105mg | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 High dose, SKY0402 Middle dose, SKY0402 low dose
C: Arm Label: Sky0402; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): Sky0402 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1 Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Group 1 Standard of Care | Arm Label: Group 2 EXPAREL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Group 2 EXPAREL | Intervention Type: DRUG; Name: Group 1 Standard of Care; Assigned to Arm(s): Group 1 Standard of Care | Intervention Type: DRUG; Name: Group 2 EXPAREL; Assigned to Arm(s): Group 2 EXPAREL

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 Via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty.
Brief Summary: Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty


Options:
A: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402
B: Arm Label: Bupivacaine HCl 105mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402 low dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 Middle dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 High dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl 105mg | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 High dose, SKY0402 Middle dose, SKY0402 low dose
C: Arm Label: IV morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate | Arm Label: EXPAREL (bupivacaine liposome injectable suspension); Type: EXPERIMENTAL; Interventions: Drug: EXPAREL (bupivacaine liposome injectable suspension) | Intervention Type: DRUG; Name: IV morphine sulfate; Assigned to Arm(s): IV morphine sulfate | Intervention Type: DRUG; Name: EXPAREL (bupivacaine liposome injectable suspension); Assigned to Arm(s): EXPAREL (bupivacaine liposome injectable suspension)
D: Arm Label: Bupivacaine and low dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine and high dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: High dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Intervention Type: DRUG; Name: Questionnaire and Physical Exam; Assigned to Arm(s): Bupivacaine, Bupivacaine and high dose SKY0402, Bupivacaine and low dose SKY0402, High dose SKY0402

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes
Brief Summary: A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: ER niacin/laropiprant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator : placebo (unspecified) | Intervention Type: DRUG; Name: ER niacin/laropiprant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator : placebo (unspecified); Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): N/A
C: Arm Label: Extended-release niacin; Type: EXPERIMENTAL; Interventions: Drug: extended-release niacin (Niaspan) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: extended-release niacin (Niaspan) | Intervention Type: DRUG; Name: extended-release niacin (Niaspan); Assigned to Arm(s): Extended-release niacin, Placebo
D: Intervention Type: DRUG; Name: niacin (+) laropiprant (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: niacin (+) laropiprant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion
Brief Summary: This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to central retinal vein occlusion (CRVO); 392 patients with CRVO were enrolled at 95 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).


Options:
A: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
C: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg
D: Intervention Type: DRUG; Name: Intravitreal Triamcinolone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radial Optic Neurotomy; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Placebo - Sham Intravitreal Injection; Assigned to Arm(s): N/A

Answer: C